Supplementary Figure 3 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling | Synapse
March 11, 2024Open Access
Supplementary Figure 3 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
Key Points
Key points are not available for this paper at this time.
Abstract
GSEA of Hallmarks pathways downregulated from 2D to 3D and upregulated upon αEGFR-E-P125A treatment